{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:02:52Z","timestamp":1768399372584,"version":"3.49.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,3,29]],"date-time":"2006-03-29T00:00:00Z","timestamp":1143590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2006,6,6]]},"DOI":"10.1007\/s00198-006-0094-1","type":"journal-article","created":{"date-parts":[[2006,3,28]],"date-time":"2006-03-28T08:14:17Z","timestamp":1143533657000},"page":"996-1007","source":"Crossref","is-referenced-by-count":46,"title":["The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective"],"prefix":"10.1007","volume":"17","author":[{"given":"F.","family":"Borgstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Sintonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Haentjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Johnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,29]]},"reference":[{"key":"94_CR1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton, LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761\u20131767","journal-title":"Lancet"},{"key":"94_CR2","unstructured":"Report on Osteoporosis in the European Community - Action for Prevention (1998). European Commission \u2013 Employment & Social Affairs"},{"key":"94_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229\u2013238","journal-title":"Osteoporos Int"},{"key":"94_CR4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018\u20132026","journal-title":"Lancet"},{"key":"94_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"94_CR6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"94_CR7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"94_CR8","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"1997","unstructured":"Drummond M, O\u2019Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford"},{"key":"94_CR9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00198-004-1643-0","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862\u2013871","journal-title":"Osteoporos Int"},{"key":"94_CR10","first-page":"36","volume":"100","author":"F Borgstrom","year":"2003","unstructured":"Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100:36\u201340","journal-title":"Lakartidningen"},{"key":"94_CR11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/qjmed\/95.5.305","volume":"95","author":"CP Iglesias","year":"2002","unstructured":"Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Quart J Med 95:305\u2013311","journal-title":"Quart J Med"},{"key":"94_CR12","first-page":"97","volume":"11","author":"WM Hart","year":"2002","unstructured":"Hart WM, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) An\u00e1lisis farmacoecon\u00f3mico del tratamiento de la osteoporosis postmenop\u00e1usica con risedronato o alendronato. REEMO 11:97\u2013104","journal-title":"REEMO"},{"key":"94_CR13","first-page":"93","volume":"23","author":"JG Brecht","year":"2003","unstructured":"Brecht JG, Kruse HP, Felsenberg D, Mohrke W, Oestreich A, Huppertz E (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93\u2013105","journal-title":"Int J Clin Pharmacol Res"},{"key":"94_CR14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322\u2013338","journal-title":"Med Decis Making"},{"key":"94_CR15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/03009749609103742","volume":"103","author":"B Jonsson","year":"1996","unstructured":"Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30\u201338","journal-title":"Scand J Rheumatol Suppl"},{"key":"94_CR16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00019053-200321050-00002","volume":"21","author":"O Johnell","year":"2003","unstructured":"Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305\u2013314","journal-title":"Pharmacoeconomics"},{"key":"94_CR17","first-page":"4112","volume":"165","author":"L Jonsson","year":"2003","unstructured":"Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165:4112\u20134116","journal-title":"Ugeskr Laeger"},{"key":"94_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1017\/S0266462399015275","volume":"15","author":"N Zethraeus","year":"1999","unstructured":"Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352\u2013365","journal-title":"Int J Technol Assess Health Care"},{"key":"94_CR19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s001980170102","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356\u2013361","journal-title":"Osteoporos Int"},{"key":"94_CR20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S8756-3282(02)00813-X","volume":"31","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26\u201331","journal-title":"Bone"},{"key":"94_CR21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/PL00004173","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120\u2013127","journal-title":"Osteoporos Int"},{"key":"94_CR22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s001980170036","volume":"12","author":"AN Tosteson","year":"2001","unstructured":"Tosteson AN, Jonsson B, Grima DT, O\u2019Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849\u2013857","journal-title":"Osteoporos Int"},{"key":"94_CR23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malm\u00f6. Osteoporos Int 11:669\u2013674","journal-title":"Osteoporos Int"},{"key":"94_CR24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(98)04235-4","volume":"353","author":"P Kannus","year":"1999","unstructured":"Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Jarvinen M (1999) Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet 353:802\u2013805","journal-title":"Lancet"},{"key":"94_CR25","unstructured":"Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. Bestuur van de gezondheidszorgen. Commissie voor toezicht op en evaluatie van statistische gegevens die verband houden met de medische activiteiten in de ziekenhuizen. Rijksadministratif centrum. Brussel. Upon written request"},{"key":"94_CR26","unstructured":"Statistiek NIvd. NIS-Dienst Verspreiding, Leuvenseweg 44, B-1000 Brussel. Upon written request"},{"key":"94_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01623349","volume":"4","author":"I Elffors","year":"1994","unstructured":"Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al. (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253\u2013263","journal-title":"Osteoporos Int"},{"key":"94_CR28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF01623689","volume":"7","author":"O Johnell","year":"1997","unstructured":"Johnell O, Gullberg B, Kanis JA (1997) The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int 7:138\u2013144","journal-title":"Osteoporos Int"},{"key":"94_CR29","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254\u20131259","journal-title":"Br Med J"},{"key":"94_CR30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468\u2013489","journal-title":"Osteoporos Int"},{"key":"94_CR31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739","journal-title":"J Bone Miner Res"},{"key":"94_CR32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u2013382","journal-title":"Bone"},{"key":"94_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517\u2013523","journal-title":"Endocr Rev"},{"key":"94_CR34","first-page":"3109","volume":"85","author":"RP Tonino","year":"2000","unstructured":"Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109\u20133115","journal-title":"J Clin Endocrinol Metab"},{"key":"94_CR35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","volume":"103","author":"JL Stock","year":"1997","unstructured":"Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291\u2013297","journal-title":"Am J Med"},{"key":"94_CR36","unstructured":"Watts N, Barton I, Olszynski W, McKeever C, McClung M, Grauer A (2005) Sustained reduction of vertebral fracture risk in the year after discontinuation of risedronate treatment. Osteoporos Int 16:[Abstract s40]"},{"key":"94_CR37","unstructured":"Statistical Yearbook of Sweden 2004"},{"key":"94_CR38","unstructured":"L\u00e4kemedelsf\u00f6rm\u00e5nsn\u00e4mndens allm\u00e4nna r\u00e5d (2003). Stockholm"},{"key":"94_CR39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00019053-199508030-00007","volume":"8","author":"J Rovira","year":"1995","unstructured":"Rovira J, Antonanzas F (1995) Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 8:245\u2013252","journal-title":"Pharmacoeconomics"},{"key":"94_CR40","unstructured":"International Society for Pharmacoeconomics & Outcomes Research. Pharmacoeconomic Guidelines Around The World. http:\/\/www.ispor.org\/PEguidelines\/countrydet.asp?c=7&t=1 . Access date: 2005-08-22"},{"key":"94_CR41","unstructured":"A proposal for methodological guidelines for economic evaluation of pharmaceuticals (1995) Belgian Society for Pharmacoepidemiology, Brussels"},{"key":"94_CR42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"94_CR43","unstructured":"Instituto Nacional de Estadistica. Tablas de Mortalidad de la Poblaci\u00f3n de Espa\u00f1a 1998\u20131999. http:\/\/www.ine.es\/inebase\/cgi\/um?M=%2Ft20%2Fp319%2Fa1998%2F&O=pcaxis&N=&L=1 . Access date: 2005-08-22"},{"key":"94_CR44","unstructured":"Statistical Yearbook of Finland (2003). Statistics Finland, Helsinki"},{"key":"94_CR45","unstructured":"Scientific Institute of Public Health, Unit of Epidemiology. Overall Mortality: Number of Deaths, Crude Rate (\/100000): Belgium 1997: Females. http:\/\/www.iph.fgov.be\/epidemio\/spma . Access date: 2004-04-22"},{"key":"94_CR46","unstructured":"Statistical Yearbook of Sweden (2004). Statistics Sweden, Stockholm"},{"key":"94_CR47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s001980050105","volume":"8","author":"A Oden","year":"1998","unstructured":"Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599\u2013603","journal-title":"Osteoporos Int"},{"key":"94_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342","journal-title":"Osteoporos Int"},{"key":"94_CR49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"94_CR50","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","volume":"105","author":"MJ Parker","year":"1991","unstructured":"Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443\u2013446","journal-title":"Public Health"},{"key":"94_CR51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","volume":"137","author":"C Cooper","year":"1993","unstructured":"Cooper C, Atkinson EJ, Jacobsen SJ, O\u2019Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001\u20131005","journal-title":"Am J Epidemiol"},{"key":"94_CR52","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","volume":"11","author":"JA Cauley","year":"2000","unstructured":"Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556\u2013561","journal-title":"Osteoporos Int"},{"key":"94_CR53","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878\u2013882","journal-title":"Lancet"},{"key":"94_CR54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/eurpub\/9.3.211","volume":"9","author":"L Lundberg","year":"1999","unstructured":"Lundberg L, Johannesson M, Isacson D, Borgquist L (1999) Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 9:211\u2013217","journal-title":"Eur J Public Health"},{"key":"94_CR55","volume-title":"Centre for health economics","author":"P Kind","year":"1999","unstructured":"Kind P, Hardman G, Macron S, UK Population Norms for EQ-5D (1999) Centre for Health Economics, University of York, York"},{"key":"94_CR56","volume-title":"Quality of life of the Finnish population as measured by the EuroQol","author":"A Ohinmaa","year":"1996","unstructured":"Ohinmaa A, Sintonen H (1996) Quality of life of the Finnish population as measured by the EuroQol. Institut Universitari de Salut Publica de Catalunya, Barcelona"},{"key":"94_CR57","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095\u20131108","journal-title":"Med Care"},{"key":"94_CR58","unstructured":"Zethraeus N, Borgstr\u00f6m F, Johnell O, Kanis J, J\u00f6nsson B (2002) Costs and quality of life associated with osteoporosis related fractures - results from a Swedish survey. Working Paper Series in Economics and Finance, 512"},{"key":"94_CR59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00198-003-1463-7","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20\u201326","journal-title":"Osteoporos Int"},{"key":"94_CR60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s001980200107","volume":"13","author":"JE Brazier","year":"2002","unstructured":"Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768\u2013776","journal-title":"Osteoporos Int"},{"issue":"Suppl 4","key":"94_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00020934","volume":"8","author":"National Osteoporosis Foundation","year":"1998","unstructured":"National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8(Suppl 4):1\u201388","journal-title":"Osteoporos Int"},{"key":"94_CR62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0272989X9901900204","volume":"19","author":"SE Gabriel","year":"1999","unstructured":"Gabriel SE, Kneeland TS, Melton LJ 3rd, Moncur MM, Ettinger B, Tosteson AN (1999) Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 19:141\u2013148","journal-title":"Med Decis Making"},{"key":"94_CR63","first-page":"132","volume":"28","author":"A Cranny","year":"2001","unstructured":"Cranny A, Coyle D, Wells G, Jolly E, Tugwell P (2001) The psychometric properties of patient preferences in osteoporosis. J Rheumatology 28:132\u2013137","journal-title":"J Rheumatology"},{"key":"94_CR64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0272989X0102100205","volume":"21","author":"LA Merlino","year":"2001","unstructured":"Merlino LA, Bagchi I, Taylor TN, Utrie P, Chrischilles E, Sumner DR, Mudano A, Saag KG (2001) Preferences for fractures and other glucocorticoid-associated adverse events among rheumatoid arthritis patients. Med Decis Making 21:122\u2013132","journal-title":"Med Decis Making"},{"key":"94_CR65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00198-004-1622-5","volume":"15","author":"I Hallberg","year":"2004","unstructured":"Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G (2004) Health-related quality of life after osteoporotic fractures. Osteoporos Int 15:834\u2013841","journal-title":"Osteoporos Int"},{"key":"94_CR66","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","volume":"15","author":"A Oleksik","year":"2000","unstructured":"Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384\u20131392","journal-title":"J Bone Miner Res"},{"key":"94_CR67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","volume":"12","author":"AN Tosteson","year":"2001","unstructured":"Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042\u20131049","journal-title":"Osteoporos Int"},{"key":"94_CR68","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s001980050178","volume":"9","author":"SE Hall","year":"1999","unstructured":"Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508\u2013515","journal-title":"Osteoporos Int"},{"issue":"Suppl","key":"94_CR69","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/03009749609103742","volume":"103","author":"B Jonsson","year":"1996","unstructured":"Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol 103(Suppl):30\u201338; discussion 39\u201340","journal-title":"Scand J Rheumatol"},{"key":"94_CR70","first-page":"646","volume":"99","author":"M Ekman","year":"2002","unstructured":"Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99:646\u2013650","journal-title":"Lakartidningen"},{"key":"94_CR71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"JA Sacristan","year":"2002","unstructured":"Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) What is an efficient health technology in Spain? Gac Sanit 16:334\u2013343","journal-title":"Gac Sanit"},{"key":"94_CR72","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/bmj.323.7324.1300","volume":"323","author":"J Raftery","year":"2001","unstructured":"Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323:1300\u20131303","journal-title":"Br Med J"},{"key":"94_CR73","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s001980200106","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Jonsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13:765\u2013767","journal-title":"Osteoporos Int"},{"key":"94_CR74","unstructured":"Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health (2001) Geneva"},{"key":"94_CR75","unstructured":"Hart W, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) An\u00e1lisis farmacoecon\u00f3mico del tratamiento de la osteoporosis postmenop\u00e1usica con risedronato o alendronato. REEMO 11"},{"key":"94_CR76","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669\u2013674","journal-title":"Osteoporos Int"},{"key":"94_CR77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/17453679709003968","volume":"68","author":"N Zethraeus","year":"1997","unstructured":"Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13\u201317","journal-title":"Acta Orthop Scand"},{"key":"94_CR78","unstructured":"Sintonen H, Vokkolainen A, Alhava E (2002) Osteoporoottisten lonkkamurtumien taloudelliset ja el\u00e4m\u00e4nlaadulliset seuraukset. Stakes Aiheita 34\u201335"},{"key":"94_CR79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s001980070102","volume":"11","author":"P Autier","year":"2000","unstructured":"Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373\u2013380","journal-title":"Osteoporos Int"},{"key":"94_CR80","unstructured":"StadsledningskontoretsRedovisningsstab (2003) Stockholms stads budgetavr\u00e4kning 2002. Stadsledningskontorets Redovisningsstab, Stockholm"},{"key":"94_CR81","unstructured":"Hujanen T (2003) Terveydenhuollon yksikk\u00f6kustannukset Suomessa vuonna 2001 Stakes Aiheita 1\/2003, Helsinki"},{"key":"94_CR82","unstructured":"Belgian Social Security System. http:\/\/www.riziv.be\/insurer\/fr\/rate\/pdf\/2004\/doctors\/raad-20041001-fr.pdf . Access date: 2005-07-02"},{"key":"94_CR83","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00019053-200422130-00006","volume":"22","author":"J Honorato","year":"2004","unstructured":"Honorato J, Gomez-Outes A, Navarro-Quilis A, Martinez-Gonzalez J, Rocha E, Planes A (2004) Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22:885\u2013894","journal-title":"Pharmacoeconomics"},{"key":"94_CR84","unstructured":"The Swedish Association of the Pharmaceutical Industry. http:\/\/www.fass.se\/LIF\/produktfakta\/artikel_produkt.jsp?NplID=19991007000217&DocTypeID=7&UserTypeID=2 . Access date: 2005-05-06"},{"key":"94_CR85","unstructured":"Yliopiston Apteekki. http:\/\/www.yliopistonapteekki.fi\/searchProductInfo.do?searchResultByProductName=OPTINATE+TABLETTI+5MG&manufacturer=AVENTI . Access date: 2005-05-03"},{"key":"94_CR86","unstructured":"Centre Belge d\u00b4Information Pharmacoth\u00e9rapeutique. http:\/\/www.cbip.be\/ggr\/index.cfm?ggrWelk=\/nindex\/ggr\/stof\/IN_R.cfm . Access date: 2005-07-25"},{"key":"94_CR87","unstructured":"Base de datos medicamentos. http:\/\/pfarmals.portalfarma.com\/default.asp . Access date: 2005-07-26"},{"key":"94_CR88","unstructured":"Priser f\u00f6r s\u00f6dra sjukv\u00e5rdsregionen - V\u00e5rdtj\u00e4nster per klinik (2003) Universitetssjukhuset i Lund"},{"key":"94_CR89","unstructured":"Osteoporosis in the European Community: A Call to Action: An audit of policy developments since 1998 (2001) International Osteoporosis Foundation"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-006-0094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-006-0094-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-006-0094-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T11:22:45Z","timestamp":1586776965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-006-0094-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,29]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,6,6]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1007\/s00198-006-0094-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,29]]}}}